Attorneys
Dan L. O'Korn
Dan's practice focuses on the business transactions important to pharmaceutical and biotech companies, including licensing and commercial transactions, FDA-related regulatory matters, asset acquisitions and divestitures, supply agreements, product development agreements and strategic alliances. Dan previously served as outside counsel to life sciences companies and in in-house counsel roles for Eli Lilly and Company, AAIPharma, Inc., Xanodyne Pharmaceuticals, Inc. and Xcellerex, Inc.
Recognition, Affiliations & Memberships
- North Carolina State Bar
- Pinnacle Award (Eli Lilly)
- Corporate Business Development Award of Merit (Eli Lilly)
- Sourcing Innovation Energizer Award (Eli Lilly)
- American Jurisprudence Award
- Advisory Committee, UF Sid Martin Biotechnology Institute
- Board Member, SEBIO
- Former Chairman, LES RTP Chapter
- Managing Partner 2017-2018
- Former member, BioLabs North Carolina Advisory Board
- Director, First Flight Venture Center (2020-present)
- Member, VCU Commercialization Advisory Board
Education
- J.D., summa cum laude, Indiana University School of Law, 1993
- B.A., Wabash College, 1989
Admissions
- North Carolina
- Indiana
Select Publications
- When Small Pharma Buys a Big Pharma Product, North Carolina Magazine, November 2006
- Negotiating a Manufacturing Agreement: What do you need to know?, Contract Pharma, March 2007
- Mediummune v. Genentech and its Aftermath, Patent Strategy and Management, June 2007
- $50 million acquisition of marketed blood pressure prescription drug franchise
- Acquisition of marketed cardiovascular prescription drug franchise from international pharmaceutical company
- $100 million acquisition of four branded product lines from international pharmaceutical company
- Acquisition of two products that served as line extensions to specialty pharmaceutical company’s already existing branded product line
- $105 million divestiture of branded multivitamin pharmaceutical product line
- $209 million divestiture of special pharmaceutical company’s Pharmaceutical Division
- Divestiture of Eli Lilly’s Sarafem®, a branded patented compound, in the U.S.
- In-licensing of pharmaceutical compound combined with a co-promotion agreement with licensor
- Worldwide out-licensing of Eli Lilly pre-clinical compound
- $211.4 million divestiture of Darvon®/Darvocet® product line in the U.S.
- Divestiture of Axid®, a branded, patented compound, in the U.S.
- Negotiation of third party manufacturing agreements for active pharmaceutical ingredient and finished pharmaceutical product, and agreements for supply of critical raw materials
- Divestiture of PCS Holding Corporation, a wholly-owned subsidiary of Eli Lilly
- International License Agreements (Russia, Japan, S. Korea) out-licensing Phase II product technology
- License, Development and Commercialization Agreement with international animal health company
- License of compound in Phase II development on behalf of specialty pharma company
- Acquisition of branded pharmaceutical from an international pharmaceutical company on behalf of specialty pharma company
- In-licensing of vaccine technology from University Technology Transfer Office
- Negotiation of supply chain agreements for proprietary product being reviewed for approval by FDA
- Collaboration Agreement for development and commercialization of biopharmaceutical equipment